These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 22340631

  • 1. Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
    Fleming MT, Sonpavde G, Kolodziej M, Awasthi S, Hutson TE, Martincic D, Rastogi A, Rousey SR, Weinstein RE, Galsky MD, Berry WR, Wang Y, Boehm KA, Asmar L, Rauch MA, Beer TM.
    Clin Genitourin Cancer; 2012 Mar; 10(1):6-14. PubMed ID: 22340631
    [Abstract] [Full Text] [Related]

  • 2. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM.
    J Clin Oncol; 2005 May 20; 23(15):3343-51. PubMed ID: 15738542
    [Abstract] [Full Text] [Related]

  • 3. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL, Ye DW, Yao XD, Dai B, Zhang SL, Shen YJ, Zhu Y, Zhang W.
    Urol Int; 2007 May 20; 79(4):307-11. PubMed ID: 18025847
    [Abstract] [Full Text] [Related]

  • 4. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
    Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ.
    Cancer; 2011 Jun 01; 117(11):2419-25. PubMed ID: 24048789
    [Abstract] [Full Text] [Related]

  • 5. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
    Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M, Hudes GR.
    Eur J Cancer; 2012 Jan 01; 48(1):85-93. PubMed ID: 22129890
    [Abstract] [Full Text] [Related]

  • 6. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators.
    Lancet; 2010 Oct 02; 376(9747):1147-54. PubMed ID: 20888992
    [Abstract] [Full Text] [Related]

  • 7. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
    Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ.
    Cancer; 2007 Aug 01; 110(3):556-63. PubMed ID: 17577218
    [Abstract] [Full Text] [Related]

  • 8. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
    Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, Winquist E, Canadian Uro-Oncology Group.
    Clin Cancer Res; 2011 Sep 01; 17(17):5765-73. PubMed ID: 21788353
    [Abstract] [Full Text] [Related]

  • 9. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone.
    Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR.
    Clin Cancer Res; 2013 Jan 01; 19(1):215-24. PubMed ID: 23136195
    [Abstract] [Full Text] [Related]

  • 10. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED.
    N Engl J Med; 2004 Oct 07; 351(15):1513-20. PubMed ID: 15470214
    [Abstract] [Full Text] [Related]

  • 11. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
    Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M, VENICE investigators.
    Lancet Oncol; 2013 Jul 07; 14(8):760-8. PubMed ID: 23742877
    [Abstract] [Full Text] [Related]

  • 12. A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.
    Sridhar SS, Canil CM, Chi KN, Hotte SJ, Ernst S, Wang L, Chen EX, Juhasz A, Yen Y, Murray P, Zwiebel JA, Moore MJ.
    Cancer Chemother Pharmacol; 2011 Apr 07; 67(4):927-33. PubMed ID: 20602233
    [Abstract] [Full Text] [Related]

  • 13. A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
    Hussain M, Rathkopf D, Liu G, Armstrong A, Kelly WK, Ferrari A, Hainsworth J, Joshi A, Hozak RR, Yang L, Schwartz JD, Higano CS.
    Eur J Cancer; 2015 Sep 07; 51(13):1714-24. PubMed ID: 26082390
    [Abstract] [Full Text] [Related]

  • 14. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
    Saad F, Ruether D, Ernst S, North S, Cheng T, Perrotte P, Karakiewicz P, Winquist E, Canadian Uro-Oncology Group.
    BJU Int; 2008 Aug 05; 102(5):551-5. PubMed ID: 18510661
    [Abstract] [Full Text] [Related]

  • 15. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
    Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA.
    J Clin Oncol; 2010 Sep 20; 28(27):4247-54. PubMed ID: 20733135
    [Abstract] [Full Text] [Related]

  • 16. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
    Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L, Heller G.
    J Clin Oncol; 2011 Jun 01; 29(16):2191-8. PubMed ID: 21483004
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.
    Raghavan D, Brandes LJ, Klapp K, Snyder T, Styles E, Tsao-Wei D, Lieskovsky G, Quinn DI, Ramsey EW.
    J Urol; 2005 Nov 01; 174(5):1808-13; discussion 1813. PubMed ID: 16217292
    [Abstract] [Full Text] [Related]

  • 18. Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.
    Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R.
    Clin Cancer Res; 2004 Dec 15; 10(24):8147-51. PubMed ID: 15623588
    [Abstract] [Full Text] [Related]

  • 19. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
    Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF.
    J Clin Oncol; 2008 Jan 10; 26(2):242-5. PubMed ID: 18182665
    [Abstract] [Full Text] [Related]

  • 20. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators.
    N Engl J Med; 2004 Oct 07; 351(15):1502-12. PubMed ID: 15470213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.